Literature DB >> 17401663

Erythropoietin in cerebrospinal fluid: age-related reference values and relevance in neurological disease.

Karin Widl1, Johannes Brettschneider, Dagmar Schattauer, Sigurd Süssmuth, Roman Huber, Albert C Ludolph, Hayrettin Tumani.   

Abstract

We aimed to establish age-related reference values for Erythropoietin (EPO) in cerebrospinal fluid (CSF) and to evaluate concentrations in neurological diseases. CSF and serum EPO was measured in controls with tension-type headache (CTTH), in patients with ALS, dementia and depression using ELISA technique. Stability experiments showed CSF EPO to be stable for two and a half months and over two thaw/freeze cycles. A positive correlation of CSF EPO with age was found (P<0.01). We found a CSF/serum EPO concentration ratio of 0.126, pointing towards an intrathecal synthesis of EPO. The ALS group showed significantly lowered CSF EPO compared to age-matched CTTH (P<0.012), whereas the dementia and depression group showed no significant differences compared to CTTH.The establishment of age-related reference values in a large cohort of controls will improve the interpretation of future CSF EPO evaluations in neurological diseases.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17401663     DOI: 10.1007/s11064-007-9286-0

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   4.414


  27 in total

1.  Tau protein in cerebrospinal fluid (CSF): a blood-CSF barrier related evaluation in patients with various neurological diseases.

Authors:  S D Süssmuth; H Reiber; H Tumani
Journal:  Neurosci Lett       Date:  2001-03-09       Impact factor: 3.046

2.  Erythropoietin therapy for acute stroke is both safe and beneficial.

Authors:  Hannelore Ehrenreich; Martin Hasselblatt; Christoph Dembowski; Lukas Cepek; Piotr Lewczuk; Michael Stiefel; Hans-Heino Rustenbeck; Norbert Breiter; Sonja Jacob; Friederike Knerlich; Matthias Bohn; Wolfgang Poser; Eckart Rüther; Michael Kochen; Olaf Gefeller; Christoph Gleiter; Thomas C Wessel; Marc De Ryck; Loretta Itri; Hilmar Prange; Anthony Cerami; Michael Brines; Anna-Leena Sirén
Journal:  Mol Med       Date:  2002-08       Impact factor: 6.354

3.  Elevated levels of erythropoietin in cerebrospinal fluid of depressed patients.

Authors:  T Nakamura; I Ebihara; N Shimada; H Koide
Journal:  Am J Med Sci       Date:  1998-03       Impact factor: 2.378

4.  Erythropoietin and erythropoietin receptor in the developing human central nervous system.

Authors:  S E Juul; D K Anderson; Y Li; R D Christensen
Journal:  Pediatr Res       Date:  1998-01       Impact factor: 3.756

Review 5.  Erythropoietin: novel approaches to neuroprotection in human brain disease.

Authors:  Hannelore Ehrenreich; Carlotta Aust; Henning Krampe; Henriette Jahn; Sonja Jacob; Manfred Herrmann; Anna-Leena Sirén
Journal:  Metab Brain Dis       Date:  2004-12       Impact factor: 3.584

Review 6.  Recombinant human erythropoietin for neuroprotection: what is the evidence?

Authors:  Tore Eid; Michael Brines
Journal:  Clin Breast Cancer       Date:  2002-12       Impact factor: 3.225

Review 7.  Amyotrophic lateral sclerosis: a review of current concepts.

Authors:  Michael Strong; Jeffrey Rosenfeld
Journal:  Amyotroph Lateral Scler Other Motor Neuron Disord       Date:  2003-09

Review 8.  Erythropoietin and the hypoxic brain.

Authors:  Hugo H Marti
Journal:  J Exp Biol       Date:  2004-08       Impact factor: 3.312

9.  Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease.

Authors:  G McKhann; D Drachman; M Folstein; R Katzman; D Price; E M Stadlan
Journal:  Neurology       Date:  1984-07       Impact factor: 9.910

Review 10.  Erythropoietin: physiology and pharmacology update.

Authors:  James W Fisher
Journal:  Exp Biol Med (Maywood)       Date:  2003-01
View more
  8 in total

1.  rhEPO Enhances Cellular Anti-oxidant Capacity to Protect Long-Term Cultured Aging Primary Nerve Cells.

Authors:  Huqing Wang; Jiaxin Fan; Mengyi Chen; Qingling Yao; Zhen Gao; Guilian Zhang; Haiqin Wu; Xiaorui Yu
Journal:  J Mol Neurosci       Date:  2017-06-21       Impact factor: 3.444

2.  Erythropoietin concentration in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis.

Authors:  P Janik; H Kwiecinski; B Sokolowska; I Niebroj-Dobosz
Journal:  J Neural Transm (Vienna)       Date:  2009-12-12       Impact factor: 3.575

3.  Progranulin as a candidate biomarker for therapeutic trial in patients with ALS and FTLD.

Authors:  Emily Feneberg; Petra Steinacker; Alexander Erich Volk; Jochen Hans Weishaupt; Marc Axel Wollmer; Adam Boxer; Hayrettin Tumani; Albert Christian Ludolph; Markus Otto
Journal:  J Neural Transm (Vienna)       Date:  2015-12-11       Impact factor: 3.575

4.  Erythropoietin: a multimodal neuroprotective agent.

Authors:  Nadiya Byts; Anna-Leena Sirén
Journal:  Exp Transl Stroke Med       Date:  2009-10-21

5.  Erythropoietin as a Neuroprotective Molecule: An Overview of Its Therapeutic Potential in Neurodegenerative Diseases.

Authors:  Federica Rey; Alice Balsari; Toniella Giallongo; Sara Ottolenghi; Anna M Di Giulio; Michele Samaja; Stephana Carelli
Journal:  ASN Neuro       Date:  2019 Jan-Dec       Impact factor: 4.146

Review 6.  Current Evidence on the Protective Effects of Recombinant Human Erythropoietin and Its Molecular Variants against Pathological Hallmarks of Alzheimer's Disease.

Authors:  José J Jarero-Basulto; Martha C Rivera-Cervantes; Deisy Gasca-Martínez; Francisco García-Sierra; Yadira Gasca-Martínez; Carlos Beas-Zárate
Journal:  Pharmaceuticals (Basel)       Date:  2020-11-26

7.  Recombinant human erythropoietin protects long-term cultured ageing primary nerve cells by upregulating the PI3K/Akt pathway.

Authors:  Huqing Wang; Ming Chen; Zhen Gao; Yu Gong; Xiaorui Yu; Haiqin Wu
Journal:  Neuroreport       Date:  2022-03-02       Impact factor: 1.837

8.  Erythropoietin and its receptors in the brainstem of adults with fatal falciparum malaria.

Authors:  Isabelle M Medana; Nicholas P J Day; Tran Tinh Hien; Nicholas J White; Gareth D H Turner
Journal:  Malar J       Date:  2009-11-22       Impact factor: 2.979

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.